Taken together, these data suggest that enrichment of ALDHbright stem-like tumor cells and the simultaneous increase in the cell surface expression of DR5, MICA, and MICB following bortezomib treatment occurs in primary patient-derived samples in addition to immortal cancer cell lines grown in adherent cell culture conditions. Here, MICB is linked to cancer.